Rachel F Tyndale
Tyndale, Rachel F., 1962-...
Tyndale, Rachel, 1962-
Tyndale, Rachel F.
VIAF ID: 16566232 (Personal)
Permalink: http://viaf.org/viaf/16566232
Preferred Forms
- 100 0 _ ‡a Rachel F Tyndale
-
-
- 100 1 _ ‡a Tyndale, Rachel F. ‡d 1962-
- 100 1 _ ‡a Tyndale, Rachel F. ‡d 1962-..
- 100 1 _ ‡a Tyndale, Rachel F., ‡d 1962-...
-
- 100 1 _ ‡a Tyndale, Rachel, ‡d 1962-
- 100 1 _ ‡a Tyndale, Rachel, ‡d 1962-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Fāmakogenomikusu : 21seiki no sōyaku to ko no iryō | |
Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. | |
Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. | |
Nicotine induces brain CYP enzymes: relevance to Parkinson's disease | |
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study | |
Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. | |
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence | |
Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation | |
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity | |
Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies | |
The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. | |
Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level | |
Nicotine-motivated behavior in Caenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acr-5 and acr-15. | |
Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data. | |
Nicotine physical dependence and tolerance in the mouse following chronic oral administration. | |
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation | |
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | |
Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo | |
Opioids: The Painful Public Health Reality | |
Organic cation transporter variation and response to smoking cessation therapies | |
Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers | |
Patterns of lapses and recoveries during a quit attempt using varenicline and behavioral counseling among smokers with and without HIV | |
Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting | |
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. | |
Pharmacogenetic Optimization of Smoking Cessation Treatment | |
The pharmacogenetics research network: from SNP discovery to clinical drug response. | |
Pharmacogenomics. | |
Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. | |
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6 | |
Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism | |
Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis. | |
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. | |
Predicting smoking abstinence with biological and self-report measures of adherence to varenicline: Impact on pharmacogenetic trial outcomes | |
Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial | |
Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. | |
Pregnancy-Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During Antepartum and Postpartum | |
Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study | |
Preparing the Way: Exploiting Genomic Medicine to Stop Smoking | |
Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. | |
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. | |
Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. | |
Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. | |
Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia. | |
Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism | |
Rate of Nicotine Metabolism and Tobacco Use among Persons with HIV: Implications for Treatment and Research | |
Rational design of novel CYP2A6 inhibitors. | |
Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. | |
Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. | |
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment | |
Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations | |
Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers. | |
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk | |
The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race | |
Relationships between smoking behaviors and cotinine levels among two American Indian populations with distinct smoking patterns. | |
Risk factors for tobacco dependence in adolescent smokers. | |
RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles | |
The role of CYP2A6 in the emergence of nicotine dependence in adolescents | |
The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo | |
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. | |
S265. Endocannabinoid Metabolism and Alcohol Consumption in Youth: A PET Study With the Fatty Acid Amide Hydrolase Radioligand [11C]CURB | |
Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice | |
Sex differences in tobacco withdrawal and responses to smoking reduced-nicotine cigarettes in young smokers. | |
Simultaneous determination of haloperidol and reduced haloperidol by gas chromatography using a megabore column with electron-capture detection: application to microsomal oxidation of reduced haloperidol | |
Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. | |
Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment? | |
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain | |
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent | |
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry | |
T76. Involvement of the Endocannabinoid Enzyme Fatty Acid Amide Hydrolase in the Neurobiology of Impulsivity: Positron Emission Tomography Studies With [11C]CURB | |
Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers | |
Tobacco use among southwestern Alaska Native people | |
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. | |
Toward Precision Medicine for Smoking Cessation: Developing a Neuroimaging-Based Classification Algorithm to Identify Smokers at Higher Risk for Relapse | |
Transferability Of Ancestry-Specific And Cross-Ancestry CYP2A6 Activity Genetic Risk Scores In African And European Populations | |
The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. | |
The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings | |
ファーマコゲノミクス : 21世紀の創薬と個の医療 |